{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:25:15Z","timestamp":1791897915254,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Governmental Funding of Clinical Research within National Health Services (ALF), Sweden"},{"name":"Swedish Breast Cancer Group"},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Personalized cancer treatment requires predictive biomarkers, including image-based biomarkers. Breast cancer (BC) patients receiving neoadjuvant chemotherapy (NACT) are in a clinically vulnerable situation with the tumor present. This study investigated whether mammographic density (MD), assessed pre-NACT, is predictive of pathological complete response (pCR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 495 BC patients receiving NACT in Sweden 2005\u20132019 were included, merged from two different cohorts. Cohort 1 was retrospectively collected (<jats:italic>n<\/jats:italic> = 295) and cohort 2 was prospectively collected (<jats:italic>n<\/jats:italic> = 200). Mammograms were scored for MD pre-NACT according to the Breast Imaging-Reporting and Data System (BI-RADS), 5th Edition. The association between MD and accomplishing pCR post-NACT was analyzed using logistic regression models\u2014for the whole cohort, stratified by menopausal status, and in different St. Gallen surrogate subtypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In comparison to patients with low MD (BI-RADS a), the multivariable-adjusted odds ratio (OR) of accomplishing pCR following NACT was on a descending scale: 0.62 (95% confidence interval (CI) 0.24\u20131.57), 0.38 (95% CI 0.14\u20131.02), and 0.32 (95% CI 0.09\u20131.08) for BI-RADS b, c, and d, respectively. For premenopausal patients selectively, the corresponding point estimates were lower, although wider CIs: 0.31 (95% CI 0.06\u20131.62), 0.24 (95% CI 0.04\u20131.27), and 0.13 (95% CI 0.02\u20130.88). Subgroup analyses based on\u00a0BC subtypes resulted in imprecise estimates, i.e., wide CIs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>It seemed as though patients with higher MD at baseline were less likely to reach pCR after NACT\u2014a finding more pronounced in premenopausal women. Larger multicenter studies are needed to enable analyses and interpretation for different BC subtypes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10552-020-01379-w","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T04:22:31Z","timestamp":1609302151000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-8649","authenticated-orcid":false,"given":"Ida","family":"Skarping","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-7624","authenticated-orcid":false,"given":"Daniel","family":"F\u00f6rnvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe","family":"Heide-J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-5199","authenticated-orcid":false,"given":"Hanna","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-9126","authenticated-orcid":false,"given":"Per","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-3882","authenticated-orcid":false,"given":"Sophia","family":"Zackrisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7938-8893","authenticated-orcid":false,"given":"Signe","family":"Borgquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"issue":"6","key":"1379_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1379_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-016-0701-9","volume":"18","author":"MJ Sherratt","year":"2016","unstructured":"Sherratt MJ, McConnell JC, Streuli CH (2016) Raised mammographic density: causative mechanisms and biological consequences. Breast Cancer Res 18(1):45. https:\/\/doi.org\/10.1186\/s13058-016-0701-9","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1379_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-014-2901-2","volume":"144","author":"CW Huo","year":"2014","unstructured":"Huo CW, Chew GL, Britt KL, Ingman WV, Henderson MA, Hopper JL, Thompson EW (2014) Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat 144(3):479\u2013502. https:\/\/doi.org\/10.1007\/s10549-014-2901-2","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1379_CR4","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaoncol.2016.6326","volume":"3","author":"NJ Engmann","year":"2017","unstructured":"Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K, Breast Cancer Surveillance C (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228\u20131236. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6326","journal-title":"JAMA Oncol"},{"issue":"9","key":"1379_CR5","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelebr RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206\u20132223. https:\/\/doi.org\/10.1093\/annonc\/mdt303","journal-title":"Ann Oncol"},{"issue":"6797","key":"1379_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752. https:\/\/doi.org\/10.1038\/35021093","journal-title":"Nature"},{"issue":"10","key":"1379_CR7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736\u2013750. https:\/\/doi.org\/10.1093\/jnci\/djp082","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1379_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelebr RD, Thurlimann B, Senn HJ, Panel M (2011) Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736\u20131747. https:\/\/doi.org\/10.1093\/annonc\/mdr304","journal-title":"Ann Oncol"},{"issue":"10","key":"1379_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast C (2019) Estimating the benefits of therapy for early-stage breast cancer: the St Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30(10):1541\u20131557. https:\/\/doi.org\/10.1093\/annonc\/mdz235","journal-title":"Ann Oncol"},{"key":"1379_CR10","unstructured":"Regionalt Cancercentrum Nationellt v\u00e5rdprogram 2020 - Br\u00f6stcancer https:\/\/kunskapsbanken.cancercentrum.se\/globalassets\/cancerdiagnoser\/brost\/vardprogram\/nationellt-vardprogram-brostcancer.pdf. Accessed 29 Sep 2020."},{"issue":"1","key":"1379_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"Early Breast Cancer Trialists' Collaborative G","year":"2018","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19(1):27\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(17)30777-5","journal-title":"Lancet Oncol"},{"issue":"18","key":"1379_CR12","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48(18):3342\u20133354. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.023","journal-title":"Eur J Cancer"},{"issue":"5","key":"1379_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.breast.2015.05.007","volume":"24","author":"S Elsamany","year":"2015","unstructured":"Elsamany S, Alzahrani A, Abozeed WN, Rasmy A, Farooq MU, Elbiomy MA, Rawah E, Alsaleh K, Abdel-Aziz NM (2015) Mammographic breast density: predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast 24(5):576\u2013581. https:\/\/doi.org\/10.1016\/j.breast.2015.05.007","journal-title":"Breast"},{"issue":"4","key":"1379_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.hemonc.2014.09.001","volume":"7","author":"CA Castaneda","year":"2014","unstructured":"Castaneda CA, Flores R, Rojas K, Flores C, Castillo M, Milla E (2014) Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma. Hematol Oncol Stem Cell Ther 7(4):149\u2013156. https:\/\/doi.org\/10.1016\/j.hemonc.2014.09.001","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"1379_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1186\/s12885-019-6485-4","volume":"19","author":"I Skarping","year":"2019","unstructured":"Skarping I, Fornvik D, Sartor H, Heide-Jorgensen U, Zackrisson S, Borgquist S (2019) Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer. BMC Cancer 19(1):1272. https:\/\/doi.org\/10.1186\/s12885-019-6485-4","journal-title":"BMC Cancer"},{"key":"1379_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.breast.2020.05.013","volume":"53","author":"I Skarping","year":"2020","unstructured":"Skarping I, Fornvik D, Heide-Jorgensen U, Sartor H, Hall P, Zackrisson S, Borgquist S (2020) Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. Breast 53:33\u201341. https:\/\/doi.org\/10.1016\/j.breast.2020.05.013","journal-title":"Breast"},{"key":"1379_CR17","unstructured":"Sickles E DOC, Bassett LW, et al (2013) ACR BI-RADS\u00ae Mammography. In: ACR BI-RADS\u00ae Atlas, Breast Imaging Reporting and Data System. American College of Radiology, Reston, VA"},{"key":"1379_CR18","doi-asserted-by":"publisher","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging. CA Cancer J Clin 67 (2):93-99. https:\/\/doi.org\/https:\/\/doi.org\/10.3322\/caac.21388","DOI":"10.3322\/caac.21388"},{"issue":"19","key":"1379_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/jnci\/djh260","volume":"96","author":"LA Habel","year":"2004","unstructured":"Habel LA, Dignam JJ, Land SR, Salane M, Capra AM, Julian TB (2004) Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst 96(19):1467\u20131472. https:\/\/doi.org\/10.1093\/jnci\/djh260","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1379_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","volume":"31","author":"S Greenland","year":"2016","unstructured":"Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG (2016) Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol 31(4):337\u2013350. https:\/\/doi.org\/10.1007\/s10654-016-0149-3","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"1379_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s13104-019-4653-x","volume":"12","author":"AA Hashmi","year":"2019","unstructured":"Hashmi AA, Hashmi KA, Irfan M, Khan SM, Edhi MM, Ali JP, Hashmi SK, Asif H, Faridi N, Khan A (2019) Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes 12(1):605. https:\/\/doi.org\/10.1186\/s13104-019-4653-x","journal-title":"BMC Res Notes"},{"issue":"6","key":"1379_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/bcr2942","volume":"13","author":"NF Boyd","year":"2011","unstructured":"Boyd NF, Martin LJ, Yaffe MJ, Minkin S (2011) Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 13(6):223. https:\/\/doi.org\/10.1186\/bcr2942","journal-title":"Breast Cancer Res"},{"issue":"6","key":"1379_CR23","doi-asserted-by":"publisher","first-page":"R104","DOI":"10.1186\/bcr3570","volume":"15","author":"KA Bertrand","year":"2013","unstructured":"Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz V, Visscher D, Norman A, Couch F, Shepherd J, Fan B, Chen YY, Ma L, Beck AH, Cummings SR, Kerlikowske K, Vachon CM (2013) Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res 15(6):R104. https:\/\/doi.org\/10.1186\/bcr3570","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1379_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/bcr1831","volume":"10","author":"LJ Martin","year":"2008","unstructured":"Martin LJ, Boyd NF (2008) Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 10(1):201. https:\/\/doi.org\/10.1186\/bcr1831","journal-title":"Breast Cancer Res"},{"key":"1379_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13058-015-0592-1","volume":"17","author":"CW Huo","year":"2015","unstructured":"Huo CW, Chew G, Hill P, Huang D, Ingman W, Hodson L, Brown KA, Magenau A, Allam AH, McGhee E, Timpson P, Henderson MA, Thompson EW, Britt K (2015) High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. Breast Cancer Res 17:79. https:\/\/doi.org\/10.1186\/s13058-015-0592-1","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1379_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1242\/dmm.004077","volume":"4","author":"TR Cox","year":"2011","unstructured":"Cox TR, Erler JT (2011) Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 4(2):165\u2013178. https:\/\/doi.org\/10.1242\/dmm.004077","journal-title":"Dis Model Mech"},{"key":"1379_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.bioeng.9.060906.151850","volume":"9","author":"MA Swartz","year":"2007","unstructured":"Swartz MA, Fleury ME (2007) Interstitial flow and its effects in soft tissues. Annu Rev Biomed Eng 9:229\u2013256. https:\/\/doi.org\/10.1146\/annurev.bioeng.9.060906.151850","journal-title":"Annu Rev Biomed Eng"},{"issue":"8","key":"1379_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583\u2013592. https:\/\/doi.org\/10.1038\/nrc1893","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1379_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1148\/radiol.2015150089","volume":"278","author":"MS Bae","year":"2016","unstructured":"Bae MS, Moon HG, Han W, Noh DY, Ryu HS, Park IA, Chang JM, Cho N, Moon WK (2016) Early Stage Triple-Negative Breast Cancer: Imaging and Clinical-Pathologic Factors Associated with Recurrence. Radiology 278(2):356\u2013364. https:\/\/doi.org\/10.1148\/radiol.2015150089","journal-title":"Radiology"},{"issue":"2","key":"1379_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10549-019-05300-1","volume":"177","author":"MS Shawky","year":"2019","unstructured":"Shawky MS, Huo CW, Henderson MA, Redfern A, Britt K, Thompson EW (2019) A review of the influence of mammographic density on breast cancer clinical and pathological phenotype. Breast Cancer Res Treat 177(2):251\u2013276. https:\/\/doi.org\/10.1007\/s10549-019-05300-1","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-020-01379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-020-01379-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-020-01379-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T02:16:17Z","timestamp":1612923377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-020-01379-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s10552-020-01379-w","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SZ and HS have received speakers\u2019 fees and travel support from Siemens Healthcare AG. SZ has received consultancy fees from Collective Minds Radiology AB. PH is a member of a scientific advisory board for: Cancer Research UK, iCAD and Atossa Genetics. SB has received speakers\u2019 fees from Pfizer, is a member of a Pfizer advisory board, and has received travel support from Roche. The other authors declare they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Regional Ethics Committee in Lund, Sweden (Committee\u2019s Reference Number: 2014\/13, 2014\/521 and 2016\/521).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Cohort 1: In accordance with the decision from the ethics committee, all living patients received a written letter asking for their consent at the time of the study. Patients declining participation were asked to provide notice to the researchers either by phone or email. Cohort 2: Informed written consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}